Strong Revenue Growth:
Revenue continues to rise at a double‑digit pace year over year with acceleration into year‑end. Management reaffirmed guidance for another year of meaningful top‑line expansion.
Market Expansion:
The customer base and analysis volumes increased to record levels, and two large U.S. integrated health systems are expected to add substantial annual throughput as implementations ramp in the second half of 2026. Net dollar retention improved, indicating deeper adoption within existing institutions.
Strategic Partnerships:
Collaborations with leading cancer centers and biopharma (e.g., MSK‑ACCESS powered with SOPHiA DDM, AstraZeneca, MD Anderson) are expanding product adoption and opening key U.S. channels. These alliances signal validation of the platform and support growth in high‑value applications like liquid biopsy.
